p53 and ras mutations in Ewing's sarcoma

Kathrin Radig, Regine Schneider-Stock, Ingeborg Röse, Uwe Mittler, Yoshinao Oda, Albert Roessner

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


The role of tumor suppressor genes and oncogenes in the development of Ewing's sarcoma has not yet been fully clarified. In this study, we analyzed the frequency of p53 tumor suppressor gene mutation in exons 4-8 by PCR-SSCP and direct sequencing, and the expression of p53-protein in Ewing's sarcoma (ES) by using immunohistochemistry. The overexpression of MDM2, which acts as a functional inactivator of p53, was studied by immunohistochemistry. In addition, a screening for point mutations in the hot spot regions codon 12 and 13 of exon 1 and codon 61 of exon 2 of ras-genes (H-ras, N-ras, K-ras) was performed. In one case, a p53 gene mutation could be confirmed in codon 238 of exon 7 (1/24). Overexpression of MDM2 was found in five cases; in ras-genes, no mutations were detected. Compared with other highly malignant mesenchymal pediatric tumors such as osteosarcomas, mutations of p53 and ras in Ewing's sarcomas are an extraordinarily rare event. However, their frequency is comparable to that of PNET, suggesting that the low incidence of these mutations in ES and PNET could be group-specific for tumors of neuroectodermal genesis.

Original languageEnglish
Pages (from-to)157-162
Number of pages6
JournalPathology Research and Practice
Issue number3
Publication statusPublished - 1998

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Cell Biology


Dive into the research topics of 'p53 and ras mutations in Ewing's sarcoma'. Together they form a unique fingerprint.

Cite this